Stockreport

India Semaglutide Patent Expiry Could Drive 50% Price Drop in Weight-Loss Drugs [Yahoo! Finance]

Dr. Reddy's Laboratories Ltd  (RDY) 
US:NYSE Investor Relations: drreddys.com/investors
PDF This article first appeared on GuruFocus India's obesity-drug market could be entering a new phase as Novo Nordisk ( NYSE:NVO ) approaches the expiration of its key s [Read more]